Michael A. Alvarez
Michael A. Alvarez is Executive Director for the MD Anderson Center for Professional Development and Entrepreneurship, which provides education and training in these areas for clinicians and researchers, and engages externally with organizations across multiple sectors to facilitate the translation of knowledge, technologies, and expertise. Prior to this role, he founded and directed the Stanford School of Medicine Career Center, establishing relationships on behalf of the University, assisting and advising start-up companies, and developing innovative curricula to support the professional advancement of physicians and biomedical scientists. Throughout more than 20 years, his professional experience spans both business and academic settings, including coaching and advising at Boston College, management consulting as part of Accenture's NYC practice, founding and directing the UCSF Center for Career & Professional Development - serving all schools and disciplines - and providing independent consultation to life science companies in the areas of business strategy and organizational design. He is widely sought for input and expert opinion on labor market trends, technology commercialization, and medical science training, and has written, reviewed, and published many articles on these topics in key venues. Michael holds bachelor's and master's degrees from Boston College, a certificate in Intellectual Property Management from the University of Washington, and studied business at IESE in Barcelona, Spain. He is an Emeritus Chair of the Bay Bio Institute, supports bio-entrepreneurship as an advisor to early stage companies, and participates actively on bioscience committees and boards both regionally and nationally.
Jeff currently serves as the Executive Director at SkyDeck | Berkeley, the University's only startup accelerator.He was the third employee of Atari's International Home Computer Division, responsible for its business development throughout Europe and the Middle East. Just as the Venture Capital communities were awakening to thepower of home computing and the serial potential of entrepreneurs in emerging digital companies, he joined former classmates as a founding team member of Electronic Arts. There he led the company's international expansion from inception until its IPO 7 years later. With the advent of the Internet and the dominating role of software development, he founded and/or led a series of software companies including License to Mail, Cardsmith, The Hive Group, and Just Arrive, all of which were the result of ideas and skills of recent university graduates from the Bay Area.Jeff obtained his undergraduate education and MBA at Stanford University and has lived in the Bay Area for the past 40 years.
Douglas Crawford's goal is to help entrepreneurial scientists create successful startups to meet California's needs for better health, a sustainable environment, and economic growth—particularly jobs. To this end, Crawford and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Crawford created and manages the first incubator within the University of California, the QB3 Garage@UCSF. The QB3 incubator program has now grown to five sites and 62 companies, and he has created a partnership to build a new 24,000 square foot life-science incubator in Mission Bay. More recently, QB3 created a program to help entrepreneurs create companies to pursue government grants and private funding. In the first 23 months this program has helped launch 150 companies, 31 of which are already operational. Crawford is also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that makes pivotal early-stage investments in bioscience companies. He is a board member of Atreca (observer), Delpor, Ethonova, Magnamosis, and Ocular Dynamics. Crawford received his PhD in biochemistry from UCSF.
Steven M. Ferguson
Steven M. Ferguson currently serves as a Deputy Director and senior licensing professional for the NIH Office of Technology Transfer, the patent & licensing office for technologies arising from the NIH and FDA intramural research programs. This technology portfolio includes about 1300 active licenses, 400 of which report product sales in aggregate greater than $6B per year. A former chemist at the National Cancer Institute, Mr. Ferguson holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor's Degree in Chemistry (Case Western Reserve University). A registered Patent Agent and a Certified Licensing Professional (CLP), Mr. Ferguson is faculty and Technology Transfer Department Chair at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH. Mr. Ferguson has published numerous articles on licensing and technology transfer and was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory. He is currently an Executive-in-Residence at the Johns Hopkins University Cary School of Business. Mr. Ferguson is a project or business reviewer for the Maryland Industrial Partnerships Program, the NIST Advance Technology Program, the Virginia Bio-Life GAP Fund, the India-U.S. Science & Technology Fund, the Federal Laboratory Consortium and faculty for the Biotechnology Industry Organization "Bio Boot Camp". He has received the AUTM President's Award, the NIH Director's Award, the FAES Instruction Award, the Federal Laboratory Consortium STEM Award and thirteen NIH Merit Awards in recognition of his service and activities in the area of technology transfer.
Mark A. Goldsmith
Mark Goldsmith has committed his entire career to medical science. Dr. Goldsmith joined Third Rock Ventures in 2012, where he contributes to the ideation, development and leadership of innovative companies. Previously, Dr. Goldsmith was president and chief executive officer of Constellation Pharmaceuticals, where he led the company to a preeminent position in the field of epigenetics and to development of a class-leading strategic relationship with Genentech/Roche. He continues active involvement with Constellation, a Third Rock Ventures portfolio company, in the role of chairman of the Board of Directors. Prior to his appointment at Constellation in 2009, he was senior executive-in-residence at Prospect Venture Partners, a leading life science investment firm, after serving as chairman and CEO of Cogentus Pharmaceuticals. Previously he was senior vice president, responsible for the health care division of Genencor International, an independent and publically listed company prior to its acquisition by Danisco. Before entering the private sector, Dr. Goldsmith led a productive biomedical research laboratory at the Gladstone Institute of Virology and Immunology, and he has co-authored 85 peer-reviewed scientific publications and is co-inventor on multiple patents. He practiced medicine on the faculty of the University of California at San Francisco (UCSF) School of Medicine and at San Francisco General Hospital, and served as a consultant to and collaborator of leading pharmaceutical and biotechnology companies. Dr. Goldsmith received his B.A. degree from Princeton University, earned his M.D. and Ph.D. in microbiology and immunology from UCSF, and conducted postgraduate medical training at Harvard Medical School and UCSF.
Corey Goodman is a scientist, educator, and biotechnology entrepreneur and investor. With a B.S. from Stanford University and Ph.D. from U.C. Berkeley, he spent 25 years as professor of neurobiology at Stanford and Evan Rauch Chair of Neurobiology at Berkeley (Dept. of Molecular and Cell Biology), where he was Howard Hughes Medical Institute Investigator and co-founder and director of the Wills Neuroscience Institute. He is currently an adjunct professor at U.C. San Francisco. Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and the recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin. Dr. Goodman moved into biotechnology to help apply biomedical discoveries to human health. He has co-founded Exelixis, Renovis, Second Genome, Ossianix, Labrys Biologics, and Solstice Biologics. He led Renovis as President and CEO from a private to public company until its acquisition by Evotec. He was recruited as President and founder of Pfizer's Biotherapeutics and Bioinnovation Center and a member of Pfizer's executive leadership team (reporting to the CEO), based on a entrepreneurial R&D model of small units at major academic and biotech hubs fostering innovative technology, drug discovery, and drug development. Today Dr. Goodman is Managing Partner of venBio Partners LLC, a strategic capital firm investing in innovative therapeutics for major unmet medical needs, based on a new model of strategic investment in partnership with Amgen, Baxter, and PPD. Dr. Goodman is Chair of the Board of Second Genome, Oligasis, Ossianix, Labrys Biologics, and Solstice Biologics. He is a member of the Board of Mirna. Amongst his many public policy roles, Dr. Goodman is on the Board of the California Council on Science and Technology, Pacific Institute, Bay Area Science and Innovation Consortium, and is former Chair of the National Research Council's (NAS) Board on Life Sciences and past President of the McKnight Endowment Fund for Neuroscience. He is an advisor to numerous biomedical foundations.
Kevin Grimes is the Co-director of the SPARK Program in Translational Research and an Associate Professor in the Department of Chemical and Systems Biology at the Stanford University School of Medicine. He received his MD from Brown University and completed his residency in internal medicine at Stanford University. Upon completion of his training, he became a Clinical Assistant Professor of Medicine at Stanford, where his primary duties included the teaching and practice of internal medicine. Grimes received a Hartford Foundation Fellowship to study health economics at the Stanford Graduate School of Business, where he obtained an MBA. He was subsequently selected as a White House Fellow and was assigned to the Department of Defense, where he served as Special Assistant to the Secretary for one year. He has since spent fifteen years in industry, working in the medical device, life science consulting, and biotechnology sectors prior to returning to Stanford to co-direct SPARK. In addition to SPARK, Grimes teaches graduate student courses on drug discovery and development and continues to teach and practice internal medicine. SPARK's two-fold mission is to advance promising research discoveries into the clinic as new therapeutics and diagnostics, and to educate faculty, post-doctoral fellows and students regarding the translational process. SPARK participants receive modest funding, education regarding translational research, and targeted mentorship on their specific projects. Over fifty volunteers from the local biotechnology, pharmaceutical, and health care investment community serve as advisors and mentors. SPARK is now in its seventh year. Approximately 50% of projects completing the program have been licensed and/or advanced to clinical trials.
Christopher S. Hayter
Christopher S. Hayter, Ph.D. serves as Executive Director of the Policy Evaluation and Transformation Group at the New York Academy of Sciences where he leads the Academy's work in program evaluation, higher education and science policy, organizational restructuring and strategic planning, and entrepreneurship research. He also serves as the project lead for Academy's capacity-building and evaluation partnerships with the governments of Malaysia and Qatar. He has nearly fifteen years of experience managing complex science and innovation policy projects at organizations such as National Governors Association, Council on Competitiveness, National Academies' Board on Science, Technology, and Economic Policy (STEP). He also worked for five years in the private sector establishing and managing new resort ventures for a large hospitality company. Prior to joining the Academy, Dr. Hayter served as Visiting Lecturer of Public Policy at the U.S. Coast Guard Academy. He holds a Ph.D. from George Washington University in Science Policy and Economics and has (co)authored numerous policy and peer-reviewed publications.
Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula's expertise consists of a unique combination of business, basic science and medical knowledge. Anula is co-founder of the "Evolvence India Life Science Fund" (EILSF), a $90 million fund established in 2006 to make investments in pharmaceutical, biotechnology, medical device and related contract service companies based in India. EILSF has made eight investments to date in the areas of generic drugs, cancer and eye care delivery and hospital consumables. Anula sits on the boards of Health Care Global, Bangalore, Ocimum BioSolutions and MapMyGenome in Hyderabad and nVision, based in San Francisco. She was previously a board member of HCG (exited to Temasek), Lipomics, which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.
Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California's life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company's rapid growth through substantial private equity financings and corporate partnerships and took the company's first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis practiced management and strategy consulting with Bain & Co. She currently serves on the boards of BayBio, NovaBay Pharmaceuticals (NBY), a publicly-traded anti-infective company, Opexa Therapeutics (OPXA), a publicly-traded cellular immune-mediated disease company, the HBS Healthcare Initiative, and is Vice Chair of the board of the California Biotechnology Foundation. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.
Stephanie Marrus is Director of the Entrepreneurship Center at the University of California, San Francisco (UCSF), the leading graduate healthcare/life science and medical institution in the US. Her mission is to start companies from UCSF inventions and to build the entrepreneurial ecosystem at the University. Since joining in 2012, she has built a robust series of courses and programs that is creating a vibrant entrepreneurial community on Campus. During a 25-year plus business career, she has worked with hundreds of companies in science- and technology-based industries as a corporate executive, business consultant and mentor, many with their technological roots at MIT, Harvard, Berkeley, Stanford and UCSF. In addition to her business career, she served as Deputy Secretary of Economic Affairs for a Massachusetts governor where she led economic development, business policy and chaired an environmental cleanup fund board. She has been president of a medical research foundation and serves on the Advisory Board of a social venture startup accelerator. Stephanie has had roles as CEO, COO and VP Business Development for public and private companies, led business development and M&A transactions, headed corporate development, strategy, marketing, communications and investor relations. Her sector experience is in technology, life sciences/healthcare and consumer products. She has translated her business experience to the classroom and teaches experiential courses in entrepreneurship globally. In addition to teaching at UCSF, Berkeley and Stanford, she has lectured in Europe, Latin America and Asia. She has been affiliated with Stanford University's Technology Ventures Program and UC Berkeley's entrepreneurship programs. She holds an MBA from the Wharton School, University of Pennsylvania, an MA from Columbia University and an AB from Cornell University.
Dr. Dushyant Pathak is Associate Vice Chancellor for Technology Management & Corporate Relations in the Office of Research at UC Davis with responsibility for InnovationAccess, which manages patents, licenses and intellectual property, the Office of Corporate Relations, which develops and manages broad-based, campus-wide strategic corporate partnerships and Venture Catalyst, a new unit with responsibility for facilitating the creation of new ventures and technology spin-outs based on university IP and faculty research. Dushyant has more than 15 years of management experience including with Fortune-500, publicly traded, entrepreneurial and start-up companies in roles through which he has led business development and intellectual property teams, commercial planning and clinical project operations activities and been in senior leadership responsible for a successful NASDAQ IPO. Dushyant has led entrepreneurial teams at the start-up and early development stage, including raising capital from investors in the role of CEO. Dushyant has also worked in venture capital with Connecticut Innovations and as the first EIR at QB3/Mission Bay Capital. He is an Adjunct Professor at the University of San Francisco's School of Management. Dushyant received his M.B.A. from the Haas School of Business, his Ph.D. in Biochemistry, Molecular Biology & Cell Biology from Northwestern University and his B.A in Natural Science & Mathematics from Bennington College. He conducted post-doctoral research as a Damon Runyon-Walter Winchell Cancer Fund Fellow and was a member of the Research Faculty at Yale University in the molecular biophysics and biochemistry department. He currently serves on the Board of Directors of Visionary Pharmaceuticals and the Sacramento Area Regional Technology Alliance.
Doug Rand is the Assistant Director for Entrepreneurship at the White House Office of Science and Technology Policy, where his work focuses on the Startup America initiative and efforts to promote entrepreneurship across the country. Prior to working at the White House, Doug served as co-founder and CEO of the innovative publishing company Playscripts, Inc., as well as a co-founder of the review aggregator StageGrade. He is a graduate of Yale Law School and the Yale School of Management, and received Master's and undergraduate degrees from Harvard, where he studied evolutionary biology.
Monica Rosoff is a Director of Alliance Management at Gilead Sciences, Inc, where she manages a diversity of R&D and commercial phase alliances. Dr. Rosoff has managed the Yale-Gilead research collaboration, a landmark academic-industry collaboration focused on the discovery of novel cancer therapies, since its inception in early 2011. Prior to Gilead, Dr. Rosoff managed R&D alliances with multiple academic and non-profit institutions and biotechnology companies for Genentech, Inc. Dr. Rosoff has a Ph.D. in Pharmacology from the University of Washington, where she was an HHMI pre-doctoral fellow, and conducted her postdoctoral work at Stanford University School of Medicine, studying Wnt signal transduction and cell adhesion. In addition to her time at Gilead and Genentech, Dr. Rosoff has worked at several biotechnology companies in program management and business development roles.
Don Ross is founder and managing director of HealthTech Capital, member and former board director of Sand Hill Angels, member of Life Science Angels, and director on several private company boards. Don is active in assembling investment syndications among angel groups and with venture firms. His investments include companies in healthtech, diagnostics, medical devices, mobile, and Internet. Don was an early pioneer in bringing together technology and health. In the 1980s, he developed healthcare software for psychological testing, health risk appraisal, health behavior change, and health monitoring. Don subsequently founded a healthcare publishing company, funded it internally, and ran it for 15 years until it was acquired. Specialty areas included allergy and asthma, skin care, psychopharmacology, and kidney health. Don is a published author, with articles; NIH-adopted literature; software products in health, psychology, and education; and two leading nutrition textbooks, currently in 5th editions, that are used by colleges and universities nationwide. Don is an honors graduate from UC Berkeley (architecture).
Adriana Tajonar manages the QB3 Startup in a Box and QB3 Accelerator programs, a core part of QB3's initiative to launch life science companies and set them up for operational success. The Startup in a Box Program allows entrepreneurs to form well-structured companies and prepare competitive SBIR applications. In 2 years, the program has formed over 150 companies, 31 of which are already operational. Adriana also runs the QB3 Accelerator Program, which aims to make companies operationally efficient by providing advice, checklists, and connections to best-in-class service providers. Adriana holds a PhD in Biological and Biomedical Sciences from Harvard University and a BS in Biology from MIT.
Dr. Tucker was born in the UK and educated in Australia. He holds a B. Sc. (Hons) and a Ph. D. in Microbiology from the University of Queensland. He also holds an MBA degree from St. Mary's College in Moraga, California. Dr. Tucker held post-doctoral research fellowships at Stanford University (with Prof. Stanley Cohen) and at the Research School of Biological Sciences at the Australian National University in Canberra Australia. He also holds an MBA degree from St. Mary's College in Moraga, California. Dr. Tucker's career began as a research scientist in agricultural biotechnology and then in technology management and business development at Advanced Genetic Sciences, DNA Plant Technology, Applied Biosystems, Celera Genomics and Paradigm Genetics. In 2003, Dr. Tucker joined the Office of Technology Transfer at the University of California, Office of the President, in Oakland CA. In 2004, Dr. Tucker became the Executive Director, Research Administration and Technology Transfer. In 2010 following a reorganization of the Office of Research and Graduate Studies, his office was renamed Innovation Alliances and Services to reflect a broader role in supporting and enhancing interactions with industry to help move technology from the laboratory to the marketplace.